Pediatric standard-risk AML with fully matched sibling donors: to transplant in first CR or not?
Allogeneic hematopoietic SCT (HSCT) for children with standard-risk AML in first CR (CR1) is controversial. We reviewed 32 consecutive children with standard-risk AML who received matched sibling donor HSCT in CR1 from 1995 to 2004. With a median follow-up of 76 months (range: 36-114), 3 year EFS was 0.74 (95% confidence interval (CI): 0.57-0.88) and the overall survival was 0.81 (95% CI: 0.66-0.93). Only one patient died as a result of TRM. Larger studies, such as the MRC-UK 10 and 12, reported 60-62% EFS. Outcome of children with standard-risk AML transplanted from a matched sibling donor in CR1 is very encouraging with minimal toxicity.
Gassas
A
A
Division of Haematology/Oncology/BMT, Hospital for Sick Children, University of Toronto, Ontario, Canada. adam.gassas@sickkids.ca
Afzal
S
S
Ishaqi
M K
MK
Finkelstein-Shechter
T
T
Rojas
M
M
Dupuis
A
A
Sung
L
L
Doyle
J
J
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007223:Infant; D015470:Leukemia, Myeloid, Acute / Q000401:mortality / Q000628:therapy*; D008297:Male; D012189:Retrospective Studies; D012307:Risk Factors; D035781:Siblings; D015996:Survival Rate; D014184:Transplantation, Homologous